Larry, who joined Thomas, McNerney in 2011, has founded and developed several successful biotechnology companies. Most recently, he was Founder, President and CEO of Covella Pharmaceuticals, a company focused on new mechanistic approaches to inflammatory diseases. Covella was acquired in 2010 by Santarus, Inc. Prior to Covella, he founded Conforma Therapeutics and served as President and CEO from inception through its acquisition by Biogen Idec in 2006. Larry was also a founder and Director of Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out from Conforma in conjunction with Biogen Idec’s acquisition; Cabrellis was subsequently acquired by Pharmion Corporation. Prior to Conforma, Larry co-founded both Athena Neurosciences, now wholly-owned by Elan Corporation, and Idun Pharmaceuticals, subsequently acquired by Pfizer. In addition to his work in private biotechnology companies, he served as President and CEO of Anadys Pharmaceuticals, a NASDAQ-listed public company developing drugs for viral diseases and oncology. Larry also has investment experience, having served as a Venture Partner with Westfield Capital Management. He holds an A.B. in Biochemical Sciences from Harvard, an M.Sc. in Physiology from University College London, and a Ph.D. in Biophysics from The Rockefeller University.